EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu und 6 weitere

Clinical and Molecular Hepatology · 01.10.2024 · 30 (4) · 771-792

DOI: 10.3350/cmh.2024.0236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2024. Verfasst von Renyu Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Ubiquitin-Conjugating Enzymes, Ubiquitination. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Shaanxi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Ubiquitination is widely involved in the progression of hepatocellular carcinoma (HCC) by regulating various cellular processes. However, systematic strategies for screening core ubiquitin-related genes, clarifying their functions and mechanisms, and ultimately developing potential therapeutics for patients with HCC are still lacking.

Methods

Cox and LASSO regression analyses were performed to construct a ubiquitin-related gene prediction model for HCC. Loss- and gain-of-function studies, transcriptomic and metabolomics analysis were used to explore the function and mechanism of UBE2S on HCC cell glycolysis and growth.

Results

Based on 1,423 ubiquitin-related genes, a four-gene signature was successfully constructed to evaluate the prognosis of patients with HCC. UBE2S was identified in this signature with the potential to predict the survival of patients with HCC. E2F2 transcriptionally upregulated UBE2S expression by directly binding to its promoter. UBE2S positively regulated glycolysis in a HIF-1α-dependent manner, thus promoting the proliferation of HCC cells. Mechanistically, UBE2S enhanced K11-linkage polyubiquitination at lysine residues 171 and 196 of VHL independent of E3 ligase, thereby indirectly stabilizing HIF-1α protein levels by mediating the degradation of VHL by the proteasome. In particular, the combination of cephalomannine, a small molecule compound that inhibits the expression of UBE2S, and PX-478, an inhibitor of HIF-1α, significantly improved the anti-tumor efficacy.

Conclusions

UBE2S is identified as a key biomarker in HCC among the thousands of ubiquitin-related genes and promotes glycolysis by E3 enzyme-independent ubiquitination, thus serving as a therapeutic target for the treatment of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsUbiquitin-Conjugating EnzymesUbiquitinationGlycolysisVon Hippel-Lindau Tumor Suppressor ProteinHumansCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHypoxia-Inducible Factor 1, alpha SubunitUbiquitin-Protein LigasesAnimalsMicePrognosis

Stichwörter der Autor:innen

GlycolysisHepatocellular carcinomaUbe2S protein, humanUbiquitinationVHL protein, human

Substanzen

Ubiquitin-Conjugating EnzymesUbe2S protein, humanVon Hippel-Lindau Tumor Suppressor ProteinVHL protein, humanHypoxia-Inducible Factor 1, alpha SubunitUbiquitin-Protein LigasesHIF1A protein, human

Autor:innen und Institutionen

  • Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China.
  • State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Fourth Military Medical University, Xi'an, China.

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Program of Shaanxi

Zitieren

APA

Zhang, R., Li, C., Zhang, S., Kong, L., Liu, Z., Guo, Y., Sun, Y., Zhang, C., Yong, Y., Lv, J., Lu, M., Liu, M., Wu, D., Zhang, T., Yang, H., Wei, D., Chen, Z., & Bian, H. (2024). UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL. Clinical and Molecular Hepatology, 30(4), 771-792. https://doi.org/10.3350/cmh.2024.0236

Vancouver

Zhang R, Li C, Zhang S, Kong L, Liu Z, Guo Y, et al. UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL. Clinical and Molecular Hepatology. 2024;30(4):771-792. doi:10.3350/cmh.2024.0236

BibTeX
@article{Zhang2024,
  author = {Zhang, Renyu and Li, Can and Zhang, Shuai and Kong, Lingmin and Liu, Zekun and Guo, Yixiao and Sun, Ying and Zhang, Cong and Yong, Yule and Lv, Jianjun and Lu, Meng and Liu, Man and Wu, Dong and Zhang, Tianjiao and Yang, Haijiao and Wei, Ding and Chen, Zhinan and Bian, Huijie},
  title = {UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  volume = {30},
  number = {4},
  pages = {771--792},
  doi = {10.3350/cmh.2024.0236}
}
Kostenlos starten →